Patents by Inventor Nels P. Nielson
Nels P. Nielson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240043542Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.Type: ApplicationFiled: October 11, 2023Publication date: February 8, 2024Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
-
Patent number: 11814431Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.Type: GrantFiled: March 10, 2020Date of Patent: November 14, 2023Assignee: FIVE PRIME THERAPEUTICS, INC.Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
-
Publication number: 20230312712Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: February 24, 2023Publication date: October 5, 2023Applicant: Alectro LLCInventors: Tina SCHWABE, Eric BROWN, Philip KONG, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL, Robert PEJCHAL, Nels P. NIELSON
-
Patent number: 11655303Abstract: The invention provides anti-CD39 antibody compositions and their use in treating cancer.Type: GrantFiled: September 15, 2020Date of Patent: May 23, 2023Assignee: Surface Oncology, Inc.Inventors: Scott Chappel, Andrew Lake, Michael Warren, Austin Dulak, Erik Devereaux, Pamela M. Holland, Tauqeer Zaidi, Matthew Rausch, Bianka Prinz, Nels P. Nielson, Sonia Das, Alison M. O'Neill
-
Patent number: 11634489Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: March 30, 2020Date of Patent: April 25, 2023Assignee: Alector LLCInventors: Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
-
Patent number: 11590224Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.Type: GrantFiled: October 22, 2019Date of Patent: February 28, 2023Assignee: Potenza Therapeutics, Inc.Inventors: Daniel Hicklin, William Winston, Cynthia S. Dugan, Nels P. Nielson
-
Publication number: 20230013293Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.Type: ApplicationFiled: March 2, 2022Publication date: January 19, 2023Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
-
Publication number: 20220372160Abstract: The invention provides anti-CD39 antibody compositions and their use in treating cancer. In some embodiments, an isolated anti-CD39 antibody is provided. Such an isolated anti-CD39 antibody binds to human CD39, wherein the antibody is optionally fully human or humanized. In some embodiments, the disclosure provides a method of enhancing, increasing and/or sustaining an anti-tumor immune response in a subject comprising administering the antibody or composition described herein to a subject having a tumor.Type: ApplicationFiled: September 15, 2020Publication date: November 24, 2022Applicant: Surface Oncology, Inc.Inventors: Scott CHAPPEL, Andrew LAKE, Michael WARREN, Austin DULAK, Erik DEVEREAUX, Pamela M. HOLLAND, Tauqeer ZAIDI, Matthew RAUSCH, Bianka Prinz, Nels P. NIELSON, Sonia DAS, Alison M. O'Neill
-
Patent number: 11453720Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.Type: GrantFiled: March 30, 2018Date of Patent: September 27, 2022Assignee: Potenza Therapeutics, Inc.Inventors: Nels P. Nielson, Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Heather Brodkin, Jose-Andres Salmeron-Garcia, Christopher James Nirschl, Philipp Steiner
-
Publication number: 20220162309Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: January 21, 2022Publication date: May 26, 2022Applicant: ALECTOR LLCInventors: Patricia CULP, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Nels P. NIELSON, Robert PEJCHAL
-
Patent number: 11306144Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.Type: GrantFiled: August 23, 2018Date of Patent: April 19, 2022Assignee: FIVE PRIME THERAPEUTICS, INC.Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
-
Publication number: 20220098312Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to NRP-1 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.Type: ApplicationFiled: October 25, 2021Publication date: March 31, 2022Inventors: Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Jose-Andres Salmeron-Garcia, Nels P. Nielson, Heather Brodkin
-
Patent number: 11254743Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: May 7, 2020Date of Patent: February 22, 2022Assignee: ALECTOR LLCInventors: Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal
-
Patent number: 11186644Abstract: Provided herein are antibodies, or antigen binding fragments thereof, that selectively bind to NRP-1 and its isoforms and homologs, and compositions comprising the antibodies, or antigen binding fragments thereof. Also provided are methods of using the antibodies, or antigen binding fragments thereof, such as therapeutic and diagnostic methods.Type: GrantFiled: January 3, 2019Date of Patent: November 30, 2021Assignee: Potenza Therapeutics, Inc.Inventors: Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Jose-Andres Salmeron-Garcia, Nels P. Nielson, Heather Brodkin
-
Publication number: 20210363268Abstract: The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.Type: ApplicationFiled: March 13, 2019Publication date: November 25, 2021Applicant: Surface Oncology, Inc.Inventors: Scott CHAPPEL, Andrew LAKE, Michael WARREN, Austin DULAK, Erik DEVEREAUX, Pamela M. HOLLAND, Tauqeer ZAIDI, Matthew RAUSCH, Bianka Prinz, Nels P. NIELSON, Sonia DAS
-
Publication number: 20210269542Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to GITR and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.Type: ApplicationFiled: March 10, 2021Publication date: September 2, 2021Inventors: Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Jose-Andres Salmeron-Garcia, Heather Brodkin, Sonja Kleffel, Nels P. Nielson
-
Publication number: 20210139581Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 7, 2020Publication date: May 13, 2021Applicant: ALECTOR LLCInventors: Patricia CULP, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Nels P. NIELSON, Robert PEJCHAL
-
Patent number: 10988545Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to GITR and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.Type: GrantFiled: February 20, 2018Date of Patent: April 27, 2021Assignee: Potenza Therapeutics, Inc.Inventors: Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Jose-Andres Salmeron-Garcia, Heather Brodkin, Sonja Kleffel, Nels P. Nielson
-
Publication number: 20210095041Abstract: The invention provides anti-CD39 antibody compositions and their use in treating cancer.Type: ApplicationFiled: September 15, 2020Publication date: April 1, 2021Applicant: Surface Oncology, Inc.Inventors: Scott CHAPPEL, Andrew LAKE, Michael WARREN, Austin DULAK, Erik DEVEREAUX, Pamela M. HOLLAND, Tauqeer ZAIDI, Matthew RAUSCH, Bianka Prinz, Nels P. NIELSON, Sonia DAS, Alison M. O'Neill
-
Publication number: 20200399394Abstract: The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.Type: ApplicationFiled: September 9, 2020Publication date: December 24, 2020Applicant: Surface Oncology, Inc.Inventors: Scott CHAPPEL, Andrew LAKE, Michael WARREN, Austin DULAK, Erik DEVEREAUX, Pamela M. HOLLAND, Tauqeer ZAIDI, Matthew RAUSCH, Bianka Prinz, Nels P. NIELSON, Sonia DAS